Physician profile
Gregory P Macaluso
NPI 1831355585
$164,600.47
in general payments reported to CMS, 2019-2025
39 companies · $3,365 in 2025
The $3,365 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $23K · 2021: $34K · 2022: $18K · 2023: $8,770 · 2024: $38K · 2025: $3,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $8,669 · Travel and Lodging: $375 · Education: $41.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $25,935.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,275.00 |
| Food and Beverage | $8,668.63 |
| Travel and Lodging | $374.62 |
| Education | $41.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39,433.39 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals LP | $32,920.24 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $32,831.33 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $26,161.07 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $10,244.18 | 2019-2020 | |
| United Therapeutics Corporation | $8,733.80 | 2020-2024 | Tyvaso |
| Medtronic, INC. | $2,470.07 | 2021-2022 | |
| Scpharmaceuticals INC. | $1,296.83 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,161.04 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,149.22 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $976.21 | 2022-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $935.74 | 2019-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $793.42 | 2019-2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $730.82 | 2019-2023 | Xarelto |
| Endotronix, INC. | $646.97 | 2021-2025 | Cordella Pulomonary Artery Pressure Sensor |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $526.45 | 2022-2024 | |
| Abiomed | $417.50 | 2021-2025 | Impella |
| Merck Sharp & Dohme LLC | $412.75 | 2021-2025 | Verquvo, Winrevair |
| Amgen INC. | $397.56 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $348.32 | 2019-2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $226.78 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.89 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $194.37 | 2021-2022 | |
| Jenavalve Technology, INC. | $162.44 | 2022 | |
| Akcea Therapeutics, INC. | $161.13 | 2019-2021 | |
| Boston Scientific Corporation | $157.50 | 2023-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| W. L. Gore & Associates, INC. | $122.35 | 2019 | |
| Tempus Ai, INC | $121.57 | 2025 | Egg-Af |
| Bridgebio Pharma, INC. | $111.42 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $111.29 | 2024-2025 | |
| La Jolla Pharmaceutical Company | $97.75 | 2019 | |
| Terumo Medical Corporation | $75.44 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $71.31 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $42.45 | 2021 | |
| Edwards Lifesciences Corporation | $37.82 | 2023 | Pascal |
| Amarin Pharma, INC. | $35.71 | 2019-2022 | |
| Lundbeck LLC | $30.09 | 2019-2020 | |
| Inspire Medical Systems, INC. | $22.09 | 2023 | Inspire |
| Chiesi USA, INC. | $15.16 | 2024 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Macaluso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.